JP5758900B2 - グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 - Google Patents
グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 Download PDFInfo
- Publication number
- JP5758900B2 JP5758900B2 JP2012531333A JP2012531333A JP5758900B2 JP 5758900 B2 JP5758900 B2 JP 5758900B2 JP 2012531333 A JP2012531333 A JP 2012531333A JP 2012531333 A JP2012531333 A JP 2012531333A JP 5758900 B2 JP5758900 B2 JP 5758900B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- mixture
- reaction
- range
- organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *OCC([C@@](C([C@]1O*)O*)O*)OC1(c(cc1Cc(cc2)ccc2O*)ccc1Cl)O* Chemical compound *OCC([C@@](C([C@]1O*)O*)O*)OC1(c(cc1Cc(cc2)ccc2O*)ccc1Cl)O* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
- Wrapping Of Specific Fragile Articles (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24714409P | 2009-09-30 | 2009-09-30 | |
| US61/247,144 | 2009-09-30 | ||
| PCT/EP2010/064120 WO2011039108A2 (en) | 2009-09-30 | 2010-09-24 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505975A JP2013505975A (ja) | 2013-02-21 |
| JP5758900B2 true JP5758900B2 (ja) | 2015-08-05 |
Family
ID=43736212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012531333A Active JP5758900B2 (ja) | 2009-09-30 | 2010-09-24 | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9024010B2 (Sortimente) |
| EP (1) | EP2486029B1 (Sortimente) |
| JP (1) | JP5758900B2 (Sortimente) |
| KR (1) | KR101813025B1 (Sortimente) |
| CN (1) | CN102574829B (Sortimente) |
| AR (1) | AR078193A1 (Sortimente) |
| AU (1) | AU2010303124B2 (Sortimente) |
| BR (1) | BR112012007085B8 (Sortimente) |
| CA (1) | CA2775962C (Sortimente) |
| CL (1) | CL2012000581A1 (Sortimente) |
| DK (1) | DK2486029T3 (Sortimente) |
| EA (1) | EA022032B1 (Sortimente) |
| ES (1) | ES2546762T3 (Sortimente) |
| HR (1) | HRP20150945T1 (Sortimente) |
| HU (1) | HUE026133T2 (Sortimente) |
| IL (1) | IL218101A0 (Sortimente) |
| IN (1) | IN2012DN02751A (Sortimente) |
| MX (1) | MX2012003048A (Sortimente) |
| NZ (1) | NZ598366A (Sortimente) |
| PH (1) | PH12012500634A1 (Sortimente) |
| PL (1) | PL2486029T3 (Sortimente) |
| PT (1) | PT2486029E (Sortimente) |
| SI (1) | SI2486029T1 (Sortimente) |
| TW (1) | TWI465458B (Sortimente) |
| WO (1) | WO2011039108A2 (Sortimente) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01422B (me) * | 2004-03-16 | 2013-12-20 | Boehringer Ingelheim Int | Derivati benzola supstituisani glukopiranozilom, ljekovi koji sadrže navedena jedinjenja, njihova primjena i njihov postupak proizvodnje |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| TW200745075A (en) * | 2005-09-08 | 2007-12-16 | Boehringer Ingelheim Int | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| JP2010507629A (ja) * | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| EP2217602B1 (en) | 2007-11-30 | 2018-08-29 | Boehringer Ingelheim International GmbH | 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| US9079905B2 (en) | 2008-09-08 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of CNS disorders |
| AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
| MA33152B1 (fr) | 2009-03-31 | 2012-03-01 | Boehringer Ingelheim Int | Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a |
| IN2012DN02751A (Sortimente) | 2009-09-30 | 2015-09-18 | Boehringer Ingelheim Int | |
| EP2483286B1 (en) | 2009-09-30 | 2016-07-13 | Boehringer Ingelheim International GmbH | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| MY170189A (en) | 2010-08-12 | 2019-07-09 | Boehringer Ingelheim Int | 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| WO2012163990A1 (en) | 2011-06-03 | 2012-12-06 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
| US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| FI2981269T3 (fi) | 2013-04-04 | 2023-09-27 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimillä |
| US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1215378A1 (zh) | 2013-04-18 | 2016-08-26 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| US9394329B2 (en) | 2013-09-27 | 2016-07-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| HUE065346T2 (hu) | 2013-12-17 | 2024-05-28 | Boehringer Ingelheim Vetmedica Gmbh | Macskafélék anyagcserezavarainak kezelése |
| WO2015101916A1 (en) | 2013-12-30 | 2015-07-09 | Mylan Laboratories Ltd. | Process for the preparation of empagliflozin |
| RS64355B1 (sr) | 2014-01-23 | 2023-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Sglt2 inhibitori za lečenje metaboličkih poremećaja kod životinja iz roda kanin |
| EP3125882B1 (en) | 2014-04-01 | 2020-05-13 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
| PL3197429T3 (pl) | 2014-09-25 | 2024-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie skojarzone inhibitorami sglt2 i agonistami dopaminy do profilaktyki zaburzeń metabolicznych u zwierząt koniowatych |
| US10294325B2 (en) | 2016-01-04 | 2019-05-21 | National Technology & Engineering Solutions Of Sandia, Llc | Halo-containing anion exchange membranes and methods thereof |
| WO2017120249A1 (en) | 2016-01-04 | 2017-07-13 | Sandia Corporation | Poly (phenylene)-based anion exchange polymers and methods thereof |
| US10053534B2 (en) | 2016-01-04 | 2018-08-21 | National Technology & Engineering Solutions Of Sandia, Llc | Functionalization of Diels-Alder polyphenylene polymers |
| WO2018069243A1 (en) | 2016-10-13 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives |
| AU2017344882A1 (en) | 2016-10-19 | 2019-03-28 | Boehringer Ingelheim International Gmbh | Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof |
| KR20250097990A (ko) | 2016-11-10 | 2025-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| CN108794548B (zh) * | 2017-04-28 | 2023-06-16 | 正大天晴药业集团股份有限公司 | 制备恩格列净及其中间体的方法 |
| EP3634970B1 (en) | 2017-06-05 | 2023-07-19 | Laurus Labs Limited | Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof |
| CN107163033A (zh) * | 2017-06-15 | 2017-09-15 | 扬子江药业集团北京海燕药业有限公司 | 一种高纯度依帕列净的制备方法 |
| CN109988161A (zh) * | 2017-12-29 | 2019-07-09 | 徐州万邦金桥制药有限公司 | 一种适合工业化生产恩格列净的制备方法 |
| CN108178751A (zh) * | 2018-01-30 | 2018-06-19 | 扬州工业职业技术学院 | 一种恩格列净中间体的合成方法 |
| US10479866B1 (en) | 2018-02-28 | 2019-11-19 | National Technology & Engineering Solutions Of Sandia, Llc | Block copolymers including poly(phenylene) and methods thereof |
| WO2019201752A1 (en) | 2018-04-17 | 2019-10-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20210275558A1 (en) | 2018-07-25 | 2021-09-09 | Boehringer Ingelheim International Gmbh | Methods for treating, pharmaceutical compositions and uses thereof |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| CN109456314A (zh) * | 2018-10-19 | 2019-03-12 | 威海迪素制药有限公司 | 一种恩格列净的制备方法 |
| WO2020089026A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| CN111233915B (zh) * | 2018-11-28 | 2023-09-22 | 上海科胜药物研发有限公司 | 一种2,3,4,6-四-o-三甲基硅基-d-葡萄糖酸内酯的制备方法 |
| CN110655511B (zh) * | 2019-05-31 | 2020-10-16 | 北京莱瑞森医药科技有限公司 | 一种高纯度恩格列净的制备和精制方法 |
| CN112812107B (zh) * | 2019-11-18 | 2024-03-15 | 上海启讯医药科技有限公司 | 一种sglt-2抑制剂及中间体的制备方法 |
| JP7441946B2 (ja) | 2019-11-28 | 2024-03-01 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用 |
| CN110759941B (zh) * | 2019-11-29 | 2022-08-30 | 上海网义化工有限公司 | 一种D-葡萄糖酸-γ-内酯及其中间体的制备方法 |
| CN110872216A (zh) * | 2019-12-06 | 2020-03-10 | 南京恒道医药科技有限公司 | 一种反应分离耦合生产(2-氯-5-碘苯基)-4-氟苯甲基酮的方法及装置 |
| CN110903315A (zh) * | 2019-12-16 | 2020-03-24 | 上海网义化工有限公司 | 一种D-葡萄糖酸-γ-内酯中间体的制备方法 |
| CN118615450A (zh) | 2020-02-17 | 2024-09-10 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途 |
| WO2021204756A1 (en) | 2020-04-07 | 2021-10-14 | Boehringer Ingelheim International Gmbh | Methods for the treatment of headache disorders |
| CN111410639B (zh) * | 2020-04-14 | 2021-02-26 | 天津法莫西医药科技有限公司 | 一种恩格列净中间体杂质的制备方法 |
| CN112194655B (zh) * | 2020-10-15 | 2022-08-09 | 通化东宝药业股份有限公司 | 一种恩格列净的制备方法 |
| KR20220068805A (ko) | 2020-11-19 | 2022-05-26 | 한미약품 주식회사 | 신규한 글루코스 유도체 |
| CN113480497B (zh) * | 2021-07-27 | 2023-02-28 | 山东铂源药业股份有限公司 | 一种恩格列净关键中间体的合成方法 |
| JP2024527434A (ja) | 2021-07-28 | 2024-07-24 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| US20240307426A1 (en) | 2021-07-28 | 2024-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
| CN114716425B (zh) * | 2022-04-11 | 2023-09-01 | 沧州那瑞化学科技有限公司 | 芳香杂环取代亚甲基的化合物的合成方法 |
| TW202412756A (zh) | 2022-05-25 | 2024-04-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含sglt-2抑制劑之水性醫藥組合物 |
| CN115231992B (zh) * | 2022-06-30 | 2024-08-27 | 济南鼎皓医药科技有限公司 | 一种(2-氯-5-碘苯基)(4-氟苯基)甲酮的制备方法 |
| CN115232179A (zh) * | 2022-08-15 | 2022-10-25 | 江西天戌药业有限公司 | 一种恩格列净中间体杂质的制备方法 |
| CN120857933A (zh) | 2023-03-06 | 2025-10-28 | 勃林格殷格翰动物保健有限公司 | 用于递送特别包含一或多种sglt-2抑制剂的液体药物组合物的系统 |
| WO2024240632A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
| WO2024240633A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan |
| CN116715569A (zh) * | 2023-05-26 | 2023-09-08 | 雅邦绿色过程与新材料研究院南京有限公司 | 一种4,4’-二氟二苯甲酮的制备方法 |
| WO2025191117A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Prevention of blood disorders in patient treated with a ppar agonist |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| NL167151C (nl) * | 1971-04-09 | 1981-11-16 | Acf Chemiefarma Nv | Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen. |
| NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
| DE2758025A1 (de) | 1977-12-24 | 1979-07-12 | Bayer Ag | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung |
| DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| JPS5639056A (en) | 1980-07-16 | 1981-04-14 | Kanebo Ltd | Preparation of n,n,n',n'-tetraacylated nucleus halogenated aromatic diamine |
| JPS58164502A (ja) | 1982-03-26 | 1983-09-29 | Chugai Pharmaceut Co Ltd | 除草用組成物 |
| US4786755A (en) * | 1985-06-03 | 1988-11-22 | Warner-Lambert Company | Diphenic acid monoamides |
| US4602023A (en) | 1985-06-03 | 1986-07-22 | Warner-Lambert Company | Diphenic acid monoamides |
| US4786023A (en) * | 1987-08-19 | 1988-11-22 | Harris Leverett D | Drafting implement holder |
| US6297273B1 (en) | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
| JPH1085502A (ja) * | 1996-09-19 | 1998-04-07 | Konica Corp | 晶析方法 |
| WO1998031697A1 (en) | 1997-01-15 | 1998-07-23 | Sankyo Company, Limited | Aryl c-glycoside compounds and sulfated esters thereof |
| JPH11124392A (ja) | 1997-10-21 | 1999-05-11 | Sankyo Co Ltd | Ｃ−グリコシル化されたアリールスズ化合物 |
| DE19846314A1 (de) | 1998-10-08 | 2000-04-13 | Basf Ag | Polyolefinnanocomposite |
| US6613806B1 (en) * | 1999-01-29 | 2003-09-02 | Basf Corporation | Enhancement of the efficacy of benzoylbenzenes |
| KR100591585B1 (ko) | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체 |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6498193B2 (en) | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
| US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
| JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | Ｃ−配糖体を含有する薬剤 |
| PL205605B1 (pl) | 2000-03-17 | 2010-05-31 | Kissei Pharmaceutical | Pochodna glukopiranozyloksybenzylobenzenu, kompozycja farmaceutyczna, zastosowanie tej pochodnej do wytwarzania kompozycji oraz pochodna benzylofenolu |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| AU9025701A (en) * | 2000-09-29 | 2002-04-15 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same |
| EP1344780A4 (en) | 2000-11-30 | 2004-01-28 | Kissei Pharmaceutical | GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION |
| TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| EP1360172A1 (en) | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
| US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| JP3698067B2 (ja) * | 2001-03-30 | 2005-09-21 | Ｊｓｒ株式会社 | 電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜 |
| DE60209343T2 (de) | 2001-04-11 | 2006-10-26 | Bristol-Myers Squibb Co. | Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren |
| DE10139416A1 (de) | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1432720A1 (en) * | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| WO2003031458A1 (en) | 2001-10-12 | 2003-04-17 | Dana-Farber Cancer Institute | Methods for synthesis of diarylmethanes |
| KR100966273B1 (ko) | 2002-02-01 | 2010-06-28 | 하이 포인트 파마슈티칼스, 엘엘씨 | 아미노알킬-치환된 아제티딘, 피롤리딘, 피페리딘 및아제판의 아미드 |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
| KR100985502B1 (ko) * | 2002-08-08 | 2010-10-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체 |
| HRP20050157B1 (en) | 2002-08-21 | 2013-01-31 | Boehringer Ingelheim Pharma | 8-[3-amino-piperidin-1-yl]-xanthines,the production thereof and the use of the same as medicaments |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| JP3567162B1 (ja) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| KR100665919B1 (ko) | 2002-11-20 | 2007-03-08 | 니뽄 다바코 산교 가부시키가이샤 | 4-옥소퀴놀린 화합물 및 ｈｉｖ 인테그라제 저해제로서의그의 용도 |
| JP4651934B2 (ja) | 2002-12-04 | 2011-03-16 | キッセイ薬品工業株式会社 | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| CN101260130A (zh) | 2003-01-03 | 2008-09-10 | 布里斯托尔-迈尔斯斯奎布公司 | 制备c-芳基葡糖苷sglt2抑制剂的方法 |
| US7164015B2 (en) | 2003-02-27 | 2007-01-16 | Bristol-Myers Squibb Company | Non-cryogenic process for forming glycosides |
| AU2004220222B2 (en) | 2003-03-14 | 2009-10-01 | Astellas Pharma Inc. | C-glycoside derivatives and salts thereof |
| US7674486B2 (en) | 2003-05-14 | 2010-03-09 | Indus Biotech Pvt. Ltd. | Synergistic composition for the treatment of diabetes mellitus |
| US7772192B2 (en) * | 2003-06-03 | 2010-08-10 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
| JP2004359630A (ja) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
| AR048376A1 (es) | 2003-08-01 | 2006-04-26 | Janssen Pharmaceutica Nv | C- glicosidos heterociclos fusionados sustituidos |
| SI1651658T2 (sl) | 2003-08-01 | 2020-12-31 | Mitsubishi Tanabe Pharma Corporation | Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija |
| EP1680414A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDAZOLE-O-GLUCOSIDE |
| JP4131216B2 (ja) | 2003-08-20 | 2008-08-13 | Ｊｓｒ株式会社 | ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜 |
| ES2322059T3 (es) | 2003-08-26 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Glucopiranosiloxi-pirazoles, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion. |
| US7375090B2 (en) * | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
| US20050085680A1 (en) * | 2003-10-21 | 2005-04-21 | Joseph Auerbach | Method for industrial decontamination |
| US7371732B2 (en) * | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
| DE10361133A1 (de) | 2003-12-22 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2005085265A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途 |
| CN1934103B (zh) | 2004-03-04 | 2011-06-01 | 橘生药品工业株式会社 | 稠杂环衍生物，包含稠杂环衍生物的药物组合物及其医药用途 |
| ME01422B (me) | 2004-03-16 | 2013-12-20 | Boehringer Ingelheim Int | Derivati benzola supstituisani glukopiranozilom, ljekovi koji sadrže navedena jedinjenja, njihova primjena i njihov postupak proizvodnje |
| DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| KR20070048188A (ko) | 2004-07-08 | 2007-05-08 | 아스텔라스세이야쿠 가부시키가이샤 | 아줄렌 유도체의 제조방법 및 이의 합성 중간체 |
| DE102004034690A1 (de) * | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| WO2006010557A1 (de) * | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| WO2006035796A1 (ja) | 2004-09-29 | 2006-04-06 | Kissei Pharmaceutical Co., Ltd. | １－（β－Ｄ－グリコピラノシル）－３－置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途 |
| DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JP2008524162A (ja) * | 2004-12-16 | 2008-07-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法 |
| JP2006176443A (ja) | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
| GB0428180D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
| GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| WO2006089872A1 (en) | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
| WO2006108842A1 (en) | 2005-04-15 | 2006-10-19 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE602006014411D1 (de) * | 2005-07-27 | 2010-07-01 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters (sglt) |
| KR100780553B1 (ko) | 2005-08-18 | 2007-11-29 | 한올제약주식회사 | 메트포르민 서방정 및 그의 제조방법 |
| US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| CA2620566A1 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200745075A (en) * | 2005-09-08 | 2007-12-16 | Boehringer Ingelheim Int | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| JOP20180109A1 (ar) | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
| WO2007039417A1 (en) | 2005-09-30 | 2007-04-12 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical preparation containing meloxicam |
| US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| PE20080251A1 (es) * | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| WO2007144175A2 (en) | 2006-06-16 | 2007-12-21 | Lek Pharmaceuticals D.D. | Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
| PE20080991A1 (es) | 2006-06-27 | 2008-09-05 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| WO2008020011A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| EP2056673A4 (en) | 2006-08-17 | 2010-06-16 | Wellstat Therapeutics Corp | COMBINATION TREATMENT FOR METABOLISM DISEASES |
| CA2664095A1 (en) | 2006-09-21 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| JP2010507629A (ja) | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
| US7879806B2 (en) * | 2006-11-06 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture |
| EA018495B1 (ru) | 2006-11-09 | 2013-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями |
| WO2008062273A2 (en) | 2006-11-20 | 2008-05-29 | Cadila Pharmaceuticals Limited | Solid oral dosage form having antidiabetic drug combination |
| ATE514692T1 (de) | 2007-01-26 | 2011-07-15 | Sanofi Aventis | Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| WO2008090210A1 (en) | 2007-01-26 | 2008-07-31 | Boehringer Ingelheim International Gmbh | Methods for preventing and treating neurodegenerative disorders |
| WO2008101938A1 (en) | 2007-02-21 | 2008-08-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| JP2010519273A (ja) * | 2007-02-21 | 2010-06-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法 |
| ITFI20070042A1 (it) | 2007-02-21 | 2008-08-22 | Laboratori Guidotti Spa | Formulazione farmaceutica e compressa comprendente detta formulazione. |
| AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| CL2008002425A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
| PL2200606T3 (pl) * | 2007-09-10 | 2018-08-31 | Janssen Pharmaceutica, N.V. | Sposób wytwarzania związków użytecznych jako inhibitory SGLT2 |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| US20100330177A1 (en) | 2008-02-05 | 2010-12-30 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| US20110015225A1 (en) | 2008-04-01 | 2011-01-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
| CN117547538A (zh) | 2009-02-13 | 2024-02-13 | 勃林格殷格翰国际有限公司 | 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
| KR101921934B1 (ko) * | 2009-02-13 | 2018-11-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도 |
| EA021796B1 (ru) * | 2009-02-13 | 2015-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы улучшения гликемического контроля и снижения жира в организме, или профилактики увеличения жира в организме, или ускорения снижения жира в организме путем применения ингибитора sglt-2 |
| UY32427A (es) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
| BRPI1012539A2 (pt) | 2009-04-16 | 2016-03-29 | Taisho Pharmaceutical Co Ltd | composições farmacêuticas |
| US8685934B2 (en) | 2009-05-27 | 2014-04-01 | Bristol-Myers Squibb Company | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
| US20110077212A1 (en) | 2009-09-25 | 2011-03-31 | Theracos, Inc. | Therapeutic uses of sglt2 inhibitors |
| IN2012DN02751A (Sortimente) | 2009-09-30 | 2015-09-18 | Boehringer Ingelheim Int | |
| EP2483286B1 (en) | 2009-09-30 | 2016-07-13 | Boehringer Ingelheim International GmbH | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| HRP20181755T1 (hr) | 2009-11-13 | 2018-12-28 | Astrazeneca Ab | Formulacije tableta s trenutnim oslobađanjem |
| JP2013523681A (ja) | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用 |
| AU2011295837B2 (en) | 2010-09-03 | 2015-06-18 | Astrazeneca Uk Limited | Drug formulations using water soluble antioxidants |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| WO2012106303A1 (en) | 2011-02-01 | 2012-08-09 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| WO2012163990A1 (en) | 2011-06-03 | 2012-12-06 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
| US20130035298A1 (en) | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| DE102011109492A1 (de) | 2011-08-04 | 2013-02-07 | GM Global Technology Operations LLC (n. d. Gesetzen des Staates Delaware) | Fahrunterstützungsvorrichtung zur Unterstützung der Befahrung enger Fahrwege |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20160000816A1 (en) | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1215378A1 (zh) | 2013-04-18 | 2016-08-26 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| EP3125882B1 (en) | 2014-04-01 | 2020-05-13 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
| US20170106009A1 (en) | 2015-10-15 | 2017-04-20 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
-
2010
- 2010-09-24 IN IN2751DEN2012 patent/IN2012DN02751A/en unknown
- 2010-09-24 CA CA2775962A patent/CA2775962C/en active Active
- 2010-09-24 HR HRP20150945TT patent/HRP20150945T1/hr unknown
- 2010-09-24 WO PCT/EP2010/064120 patent/WO2011039108A2/en not_active Ceased
- 2010-09-24 ES ES10762899.2T patent/ES2546762T3/es active Active
- 2010-09-24 NZ NZ598366A patent/NZ598366A/en unknown
- 2010-09-24 PH PH1/2012/500634A patent/PH12012500634A1/en unknown
- 2010-09-24 DK DK10762899.2T patent/DK2486029T3/en active
- 2010-09-24 PT PT107628992T patent/PT2486029E/pt unknown
- 2010-09-24 EP EP10762899.2A patent/EP2486029B1/en active Active
- 2010-09-24 BR BR112012007085A patent/BR112012007085B8/pt active IP Right Grant
- 2010-09-24 EA EA201200537A patent/EA022032B1/ru not_active IP Right Cessation
- 2010-09-24 CN CN201080042705.XA patent/CN102574829B/zh active Active
- 2010-09-24 SI SI201031009T patent/SI2486029T1/sl unknown
- 2010-09-24 KR KR1020127008072A patent/KR101813025B1/ko active Active
- 2010-09-24 JP JP2012531333A patent/JP5758900B2/ja active Active
- 2010-09-24 PL PL10762899T patent/PL2486029T3/pl unknown
- 2010-09-24 AU AU2010303124A patent/AU2010303124B2/en active Active
- 2010-09-24 HU HUE10762899A patent/HUE026133T2/en unknown
- 2010-09-28 US US12/892,326 patent/US9024010B2/en active Active
- 2010-09-29 TW TW099133084A patent/TWI465458B/zh active
- 2010-09-29 AR ARP100103544A patent/AR078193A1/es active IP Right Grant
- 2010-10-20 MX MX2012003048A patent/MX2012003048A/es active IP Right Grant
-
2012
- 2012-02-14 IL IL218101A patent/IL218101A0/en active IP Right Grant
- 2012-03-02 CL CL2012000581A patent/CL2012000581A1/es unknown
-
2015
- 2015-04-07 US US14/680,318 patent/US9873714B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5758900B2 (ja) | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 | |
| WO2015101916A1 (en) | Process for the preparation of empagliflozin | |
| WO2019208571A1 (ja) | アミダイト化合物及び該化合物を用いたポリヌクレオチドの製造方法 | |
| EP3483161B1 (en) | Intermediates used to make entecavir | |
| JP2021193102A (ja) | １−シアノ−２−（４−シクロプロピル−ベンジル）−４−（β−Ｄ−グルコピラノス−１−イル）−ベンゼン、Ｌ−プロリンおよび水からなる１：１：１共結晶の合成 | |
| HU207288B (en) | Process for enenthioselective producing phenyl-isoserine derivatives | |
| JP2007538041A (ja) | ジフェニルアゼチジノン誘導体の製造方法 | |
| KR100634249B1 (ko) | 파클리탁셀 ｃ-4 메틸 카르보네이트 동족체의 제조 방법 | |
| JP2021534174A (ja) | Ｓｇｌｔ阻害剤の合成に有用な中間体の製造 | |
| JP3138834B2 (ja) | フコピラノース類縁体の製造方法およびその合成中間化合物 | |
| CN101277966A (zh) | 合成HMG-CoA还原酶抑制剂的方法 | |
| RU2394835C2 (ru) | Способ получения тиофенгликозидных производных | |
| AU677986B2 (en) | N-substituted 2-azetidinones | |
| KR101032761B1 (ko) | 도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체 | |
| EP2164839A2 (en) | Process for the preparation of orlistat | |
| JPWO2003080561A1 (ja) | ボグリボースの製造法 | |
| KR20160098495A (ko) | 엠파글리플로진의 제조방법 | |
| JPH0267250A (ja) | ２，２‐ジフルオロ‐３‐ヒドロキシカルボン酸誘導体の製造法 | |
| JP2021095367A (ja) | Ｃ−アリールグリコシド誘導体の製造方法 | |
| JPH0558435B2 (Sortimente) | ||
| JP2002356492A (ja) | 非天然型糖誘導体の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140219 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150108 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150518 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150604 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5758900 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |